Table 1 Summary of trials mentioned in current review
Type of DLI | Authors | Case number | Mean age of patients (years) | Pre-DLI treatment(s) | Diagnosis | DLI modality | T cell dosage | Series of DLI (mean) | GVHD | Response rate (CR) |
|---|---|---|---|---|---|---|---|---|---|---|
Therapeutic DLI | ||||||||||
 Lymphodepletion (LDP) | Warlick et al. [7] | 35 | 51 | LPD | ALL, AML, MDS, NHL, CLL, MM | Unstimulated leukapheresis | 0.5 × 108/kg 1 × 108/kg | 1 | II–IV (25%) II–IV (66%) | CR 45% CR 53% |
Guillaume et al. [36] | 18 | 45 | Escalation LDP | ALL, AML, MDS, NHL, HD, MM | Not mentioned | 1–5 × 107/kg | 1–3 | II–IV (29.4%) | CR 38.9% | |
 With pharmacotherapy | Schroeder et al. [16] | 154 | 55 | 5-Azacytidine | AML, MDS | Not mentioned | 31.2 × 106/kg (mean) | 1–3 | Acute (23%) | CR 27% |
Schroeder et al. [17] | 30 | 55 | Azacitidine | AML, MDS | Dose-escalating donor lymphocyte | 1.5 × 106/kg–1.5 × 108/kg | 1–4 | II–IV (30%) | CR 38.1% | |
 G-CSF-primed | Yan et al. [48] | 50 | 22 | Chemotherapy | ALL, AML | G-CSF primed | 0.9–4.2 × 108/kg | 1 | II–IV (62.7%) | CR 32% |
 Prophylactic | Wang et al. [47] | 123 | 40 | No treatment | ALL, AML | Prophylactic (G-CSF primed type) | 1.8 × 108/kg | Not mentioned | II–IV (17%) | Not mentioned |
Kumar et al. [39] | 18 | 60 | Immunosuppressive therapy | ALL, AML, MDS | Prophylactic ex vivo costimulated T cells | 1–10 × 107/kg | 1–2 | Acute (27.8%) | CR 4 of 18 | |